Peucedanocoumarin III

Cat. No.: HY-122958 Purity: 95.07%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Peucedanocoumarin III is an α-synuclein fiber depolymerizer with blood-brain barrier permeability. Peucedanocoumarin III depolymerizes β-sheet aggregate structures, promotes aggregate clearance, inhibits β23-induced cytotoxicity, blocks the formation of Lewy body-like inclusions, and prevents dopaminergic neuron loss. Peucedanocoumarin III can be used in studies related to Parkinson's disease.

For research use only. We do not sell to patients.

Peucedanocoumarin III Chemical Structure

CAS No. : 130464-57-2

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	Get quote	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All α-synuclein Isoform Specific Products:

View All Isoforms

α-synuclein α-synuclein Aggregation α-synuclein/CHMP2B

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

α-synuclein Aggregation

In Vitro

Purified and synthetic Peucedanocoumarin III (1 µM; 37-48 h) similarly clear β23 aggregates and protect SH-SY5Y cells from β23-induced toxicity^[1].
Synthetic Peucedanocoumarin III partially protects protects HA-α-synuclein-transfected SH-SY5Y cells from 6-OHDA-induced cytotoxicity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	Brain Concentration
Mice^[1]	10 mg/kg	i.p.	230 ng/g

In Vivo

Peucedanocoumarin III (1 mg/kg/day; i.p.; daily; 7 days) prevents Lewy-like inclusion formation, dopaminergic neuron loss, striatal nerve terminal damage, and neuroinflammation in a 6-OHDA-induced Parkinson's disease mouse model^[1].
Peucedanocoumarin III (10 mg/kg/day; i.p.; daily; 7 days) is well-tolerated in healthy mice, shows no adverse effects on body weight, motor function, or tissue structure, and penetrates the blood-brain barrier to reach therapeutic target tissue^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6N (male, 2 months old, intrastriatal stereotaxic injection of 6-OHDA)^[1]
Dosage:	1 mg/kg/day
Administration:	i.p.; daily; 7 days
Result:	Substantially reduced phospho-serine 129 α-synuclein (pS129-α-Syn) positive Lewy-like inclusion intensities. Largely alleviated 6-OHDA-induced dopaminergic neuron loss in the substantia nigra pars compacta. Substantially protected against 6-OHDA-induced loss of striatal dopaminergic nerve terminals. Reduced 6-OHDA-induced GFAP immunofluorescence signal increase by about two-fold relative to PBS controls.

Animal Model:	C57BL/6N (male, 2 months old)^[1]
Dosage:	10 mg/kg/day
Administration:	i.p.; daily; 7 days
Result:	Showed no statistically significant difference in body weight relative to DMSO controls. Showed no statistically significant differences in total open field exploration distance, time/distance spent in arena zones, rotarod latency/speed, or pole test time to ground relative to DMSO controls. Distributed to all tested tissues, with brain levels of 230 ng/g tissue, heart levels of 231 ng/g tissue, lung levels of 121 ng/g tissue, liver levels of 105 ng/g tissue, kidney levels of 162 ng/g tissue, and spleen levels of 109 ng/g tissue. Showed no structural abnormalities in heart, lung, liver, kidney, or spleen via H&E staining. Showed no statistically significant difference in GFAP immunofluorescence signal in cortex, hippocampus, striatum, or ventral midbrain relative to DMSO controls.

Molecular Weight

386.40

Formula

C₂₁H₂₂O₇

CAS No.

130464-57-2

Appearance

Solid

Color

White to off-white

SMILES

C/C=C(C)/C(O[C@@H]1C2=C(OC(C)([C@H]1OC(C)=O)C)C=CC(C=C3)=C2OC3=O)=O

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Purity & Documentation

Purity: 95.07%

Select Batch:

Data Sheet (280 KB) SDS (251 KB)

COA (258 KB) HNMR (248 KB) LCMS (100 KB)

Handling Instructions (2659 KB)

References

[1]. Ham S, et al. Therapeutic Evaluation of Synthetic Peucedanocoumarin III in an Animal Model of Parkinson's Disease. Int J Mol Sci. 2019;20(21):5481. Published 2019 Nov 4.

[2]. Jiang J, et al. Growth Year and Chemotype Synergistically Regulate Coumarin Accumulation and the Associated Transcriptional Profiles in Peucedanum praeruptorum Dunn. Plants (Basel). 2026 Feb 13;15(4):598.

[3]. Chen IS, et al. Coumarins and antiplatelet aggregation constituents from Formosan Peucedanum japonicum. Phytochemistry. 1996;41(2):525-530. [Content Brief]